Main Content

Search loading...

MOSAIQ® Status

MOSAIQ v2.6 is under development to support Meaningful Use in 2014.

MOSAIQ v2.6 has completed beta evaluation for most functionality in the U.S. and has been moved to pilot status. This release represents our most expansive beta process to date, involving the most customers and internal resources to report and resolve issues prior to general release. These customers are using MOSAIQ v2.6 in their live clinical environments and overall feedback has been positive.

The next step in our release plan is to upgrade a much larger group of MOSAIQ systems to v2.6 to Pilot Release. These upgrades began in August and will continue into September 2014. General release is anticipated later that month.

The precise release date for MOSAIQ version 2.6 is still to be confirmed. At this time, a number of sites in North America are participating in the beta evaluation in their clinical environments. On May 30, MOSAIQ v2.6 received certification under the Drummond Group's Electronic Health Records Office of the National Coordinator Authorized Certification Body (ONC-ACB) program. This EHR software is compliant in accordance with the criteria adopted by the Secretary of the U.S. Department of Health and Human Services.

Our process begins with a release of software to our beta release group, where the software is deployed to clinical environments and extensive live testing can continue. This beta period is managed carefully through the product development group for software. Once the beta sites have tested the software and the product development team is satisfied with the functionality, stability, and performance of the release, it is released to a pilot stage. This pilot release could be installed at anywhere from a dozen to  more than 100 sites, representing a selected cross section of customer profiles, as they continue to put the release through its paces. Performance is carefully monitored by the regional support team to ensure performance and stability, at which time it will be cleared for general (or production) release.

As we complete the engineering/testing and deploy the software to beta and pilot customers, we look forward to being able to provide more clarity surrounding release so that you can plan accordingly.

We understand activities and resources require firm dates and will work with you to provide the most accurate timelines we can for an upgrade.

Elekta MOSAIQ 2.6 Complete Ambulatory Compliance Certificate


Responsibility for compliance with meaningful use regulations and guidelines rests entirely with the eligible professional or delegate.

Elekta makes no representation of expertise in the meaningful use objectives. Elekta advises each eligible professional or delegate to seek its own counsel or advisors in determining how best to interpret, apply, and comply with the meaningful use objectives.

Any training and documentation provided by Elekta are for informational and reference purposes only. Elekta makes no representation, warranty, or guarantee of completeness, accuracy, applicability, or validity of the training and documentation provided. Elekta disclaims liability for any loss or claimed damages that may arise from reliance on or use of information contained in any training and documentation provided by Elekta.

Elekta makes no representation, warranty, or guarantee that an end user of the MOSAIQ® oncology information system will meet the requirements for meaningful use, qualify for any incentive payments related to meaningful use, or demonstrate adequate compliance with meaningful use to avoid adjustments to Medicare reimbursements.

Price Transparency Statement

This certified product-version may incur one-time costs to establish functionality to meet Stage 1 or Stage 2 Requirements as follows:

  • Software License Fees, Implementation Costs and Annual Maintenance Costs (once in live use) Clinical Decision Support, ePrescribing, Patient Portal, Syndromic Surveillance, Immunizations Interface, Clinical Quality Measures Reporting Export, ICD to SNOMED Translation Engine and CCDA Export Interface to HIS.
  • One-time costs for enrollment Direct Messaging (paid to third party).
  • Ongoing annual costs are required for Drug Formulary Updates, Patient Portal subscription.

Your Feedback:

Send message Close window